Intact PTH Detection Service
Creative BioMart Biomarker provides intact PTH testing outsourcing services for scientists in the field of biomarkers or disease researches. The service results ensure accuracy, specificity and repeatability.
Our testing services are only suitable for scientific research, not intended for clinical diagnosis and testing.
|
Intact PTH Testing |
| Analyte: |
intact PTH |
| Synonyms: |
intact parathyroid hormone |
| Sample Type: |
serum, plasma, etc. |
| Assay Platform: |
ECL, IRMA |
| Biomarker Application Area: |
hypoparathyroidism, hyperparathyroidism, hypocalcemia, hypercalcemia, osteoporosis, etc. |
| * Perform three replicate tests on each sample, and include appropriate controls in each assay. |
Assay Background
Figure 1. Parathyroid hormone assay (Kakuta, et al. 2018)
PTH is a polypeptide hormone secreted by the parathyroid glands that contains 84 amino acids. It mainly acts on bone and kidney. The secretion of PTH is in response to a decrease in serum calcium levels, which increases calcium levels in the blood by increasing the renal reabsorption of calcium. In osteocyte cell lines, PTH reduces the expression level of sclerostin which is mainly expressed in osteocytes as an inhibitor of Wnt signaling, thus PTH provides another paracrine mechanism that may stimulate osteoblast differentiation. Intact PTH is the second-generation immunoassays system for evaluating the activity of PTH in which both PTH (1-84) and PTH (7-84) fragments were detected. Intact PTH assays utilize two different monoclonal antibodies, one is a solid phase capture antibody directed against the C-terminal region of PTH, and the other is a detection antibody directed against the N -terminal region. The combination of these two antibodies makes intact PTH system considered to be more specific as they avoid cross-reactivity with C-terminal PTH fragments. Diseases due to too little or too much PTH can cause bone disease, hypocalcemia and hypercalcemia, and intact PTH is a widely used PTH detection system, therefore, intact PTH detection is essential for bone pathophysiology and disease research.
Workflow of Biomarker Detection Services at Creative BioMart Biomarker
Customers provide: samples, reagents/kits (reagents/kits can also be provided or purchased by our company).
We provide: remaining samples and reagents, complete experimental reports (including experimental raw data, experimental procedures, instrument and reagent information, and professional result analysis).
Test cycle: 10 working days or less.
Why Choose Creative BioMart Biomarker for intact PTH Detection Service?
- High-quality technology platform
Creative BioMart Biomarker provides two technology platforms for intact PTH testing, ECL and IRMA. For the detection of biomarkers, our experts have optimized the technology platform to improve the sensitivity and specificity of the detection.
- Experienced experts team
Our experts have extensive experience in biomarker testing, and will perform each test in full accordance with standard experimental operating procedures to ensure that the test results delivered are accurate and repeatable.
- Suitable for multiple sample types
Our biomarker testing service is applicable to several sample types, including serum, plasma, etc. If your sample type is not common, you can contact us at any time to inquire about the testing service for your sample type.
- Fast testing and reasonable price
We have been committed to providing customers with efficient services to ensure that the experimental results are delivered within the predetermined time. Our testing services have reasonable and competitive prices in the industry, which can help customers reduce research costs.
If you are interested in our services, please feel free to contact us, Creative BioMart Biomarker is here to offer you professional and thoughtful service.
References:
- Kim, J. H.; et al. Intermittent PTH administration improves alveolar bone formation in type 1 diabetic rats with periodontitis. Journal of Translational Medicine. 2018, 16(1): 70.
- Koda, R.; et al. Intact parathyroid hormone and whole parathyroid hormone assay results disagree in hemodialysis patients under cinacalcet hydrochloride therapy. Clinical & Experimental Nephrology. 2015, 19(4): 710-717.
- Couchman, L.; et al. LC-MS candidate reference methods for the harmonisation of parathyroid hormone (PTH) measurement: a review of recent developments and future considerations. Clinical Chemistry and Laboratory Medicine. 2014, 52(9): 1251-1263.
- Kakuta, T.; et al. Critical governance issue of parathyroid hormone assays and its selection in the management of chronic kidney disease mineral and bone disorders. Therapeutic Apheresis and Dialysis. 2018, 22(Suppl 3).
